Email

Print

Tweet

Digg!

Del.icio.us

Investor Call to Be Held Today at 11:00am EST

Dallas, TX and New York, NY, December 7, 2011 – ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that an oncology supportive care nurse, Michelle Devries, was interviewed this week on the WWSB-ABC Tampa News at Noon segment covering the common side effects of cancer treatments, specifically oral mucositis, and the positive clinical benefit seen when using MuGard. In the interview, Devries provides insight to her experience with the debilitating effects of oral mucositis and debilitating effects of oral mucositis and references MuGard as the preferred treatment option for her and her patients. The interview can be viewed by clicking on the following link, http://youtu.be/K3QpFNRd47s.

Conference Call Details:
The investor conference call is scheduled to be this morning, Wednesday, December 7, 2011 at 11:00 am EST. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

A replay of the call will be available starting on December 7th at 1:00 pm EST , through December 21, 2011 until 11:59 pm EST . Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID #383500.

About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments characterized by inflammation and ulceration of the mouth, tongue and throat. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, please visit www.MuGard.com.

About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Company Schedules Investor Conference Call For Wednesday, December 7th at 11:00AM EST

DALLAS and NEW YORK, November 15, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, has announced its third quarter 2011 investor conference call and the recent progress in its MuGard program.  MuGard is a mucoadhesive oral wound rinse and coating that has been shown to be effective in the management of oral mucositis, a debilitating side effect of many anticancer treatments.  The investor conference call is scheduled to be held on Wednesday, December 7, 2011 at 11:00 am EST.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five minutes before the start time.

“We continue to be pleased with MuGard progress and our ability to better service the demand created in the oncology community,” said Frank Jacobucci, Vice President, Sales and Marketing.  He continued, “The increased payer acceptance of MuGard seen over the last few months, including October, is very encouraging and supports our belief that MuGard is becoming a preferred treatment option in the management of oral mucositis.  We look forward to updating investors of the continued growth of the MuGard program.”

Anthony Mottola, Vice President Managed Care and Market Access stated, “We continue to see significant progress with MuGard reimbursement and increased momentum in advancing discussions with additional payers and major PBM’s to ensure MuGard access to its plan memberships.  A keen focus on increased reimbursement and shipments will allow us to continue ramping MuGard revenue.”

Third Quarter 2011 Highlights:

• MuGard Prescriptions Continue to Grow:  MuGard prescriptions continued to increase through the third quarter and into the 4Q11.  Clinicians prescribing MuGard continue to provide feedback and anecdotal evidence of positive clinical experiences.  Over 700 clinicians have prescribed MuGard for their patients and over 75% of these doctors are recurring prescribers.
• Payer Uptake:  Throughout the third quarter and into 4Q11, Access made significant progress in increasing reimbursement for MuGard.  MuGard continued receiving reimbursement from many networks of leading insurance companies and pharmacy benefit managers including Group Health Incorporated (GHI), TRICARE, Harvard Pilgrim, Humana and ExpressScripts.  Reimbursement has more than doubled and now includes payers such as several state Anthem plans, various Aetna and Cigna plans, Assurant Health, Keystone, Premera and additional BlueCross Blue Shield (BCBS) and United Healthcare state plans.
• MuGard PRSC and Increased Distribution: Since its launch last quarter, Access’ MuGard Patient Reimbursement and Support Center (PRSC), also known as the MuGard HUB, has improved patient access to MuGard by enhancing product distribution and facilitating payment for MuGard by insurance carriers.  In addition to the MuGard HUB, in the third quarter, Access also brought on several specialty pharmacies including CSPN (Community Specialty Pharmacy Network) and CuraScript, the specialty division of Express Scripts, to further expand its specialty pharmacy and third party logistics networks. CSPN and CuraScript began providing MuGard to the patients within their expansive network.  CuraScript Specialty Distribution, its third party logistics division, warehouses MuGard and serves as its specialty distributor and wholesaler for specialty pharmacy providers.
• Building Demand:  Access has spent significant resources on creating and building demand throughout the U.S.  Part of the effort included an extensive sampling to reach patients, caregivers, and the oncology community.  The formulary process in local hospitals and large institutions are well underway with many decisions to be made by the end of 2011.
• Salesforce Management:  Access’ contracted sales reps continue their broad-scale marketing push for MuGard.  In the quarter, Access identified under-resourced geographic areas and allocated additional coverage in these underserved areas and in new territories as it solidifies reimbursement activities and gains additional payer acceptance.  In addition, Access continues to have discussions with potential co-promotion partners.

Conference Call Details:

The investor conference call is scheduled to be held on Wednesday, December 7, 2011 at 11:00 am EST.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

A replay of the call will be available starting on December 7th at 1:00 pm EST, through December 21, 2011 until 11:59 pm EST.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID #383500.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Dallas and New York, November 2, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it has entered into definitive agreements for the purchase of $5.2 million of units, consisting of Access common stock and warrants in a private placement financing with a select group of institutional and accredited investors.  Each unit consists of the one share of common stock at $1.45 share price, with 50% warrant coverage with an exercise price of $1.67 per share and a term of two and half years and 50% warrant coverage with an exercise price of $2.00 per share and a term of five years.  The Company is required to file a resale registration statement within 30 days following the closing that covers the resale by the investors of the shares and the shares issuable upon exercise of the warrants. The transaction is expected to close on or about November 7, 2011, subject to the satisfaction of customary closing conditions.

“We believe this financing gives us the necessary resources to advance MuGard significantly in the United States and globally,” said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc.  He continued, “We appreciate the continued support of our investors.”

Cowen and Company, LLC and Rodman & Renshaw LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., acted as the exclusive co-placement agents for the offering.

The securities issued in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were issued and sold in a private placement pursuant to Regulation D of the Securities Act.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Dallas and New York, October 14, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has updated its MuGard website to include a clinical feedback video.  The video features a late-stage colorectal patient and seasoned oncology nurse practitioner’s experience with oral mucositis and MuGard.  The video also features clips from Access’ recent manufacturing run for MuGard.  The clinical experience video will be utilized in Access’ public relations marketing efforts for MuGard.

The video can be viewed by visiting www.MuGard.com com and clicking on the “Testimonials” tab on the home page or by clicking on the following link: http://www.mugard.com/testimonials/.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments characterized by inflammation and ulceration of the mouth, tongue and throat. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Recent MuGard Reimbursement More Than Doubles Over the Past Few Months

Dallas and New York, October 13, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the reimbursement for its lead product for oral mucositis, MuGard, has increased significantly over the past few months.  Over the past few months, Access has more than doubled the amount of payers providing coverage for MuGard in the U.S.; growing from approximately 30 payers to over 70 payers and pharmacy benefit managers (PBM’s).  MuGard continues being covered by these third party payer programs with standard pharmacy benefit copayment.

On the heels of its full-scale six month sampling initiative commenced less than a year ago, Access launched MuGard in the United States and focused its efforts on growing clinical experience, building demand and increasing reimbursement coverage. As recently announced, MuGard has received reimbursement from many networks of leading insurance companies and pharmacy benefit managers throughout the United States, including several Blue Cross Blue Shield state plans, Amerigroup, TRICARE, Harvard Pilgrim, Humana and Express Scripts.   Since then, reimbursement has more than doubled and now includes payers such as several state Anthem plans, various Aetna and Cigna plans Assurant Health, Keystone, Wellspan Plus and additional BlueCross Blue Shield (BCBS) and United Healthcare state plans.

“We are pleased to see the execution of our integrated payer strategy moving us closer to nationwide reimbursement for MuGard,” said Anthony Mottola, VP Managed Care and Market Access, Access Pharmaceuticals, Inc.  He continued, “The progress made within our Payer/PBM outreach programs continues to validate our efforts to advance reimbursement and market access for MuGard.”

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Dallas and New York, September 28, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced the findings of an independent presentation on MuGard clinical experience at the 2011 European Multidisciplinary Cancer Congress held in Stockholm, Sweden. The ongoing research study was conducted by the Oncology and Maxillofacial Departments of the Musgrove Park Hospital in Taunton, United Kingdom.  In the study, 20 head and neck cancer patients were prospectively assessed for MuGard efficacy and tolerability, and compared to a historical comparison group of head and neck cancer patients. The highlights of the results, discussion and conclusions of the study included:

-MuGard was effective in prevention, delay and management of radiotherapy (RT) and chemo-radiotherapy (C-RT) induced oral mucositis, as well as reducing the need for opiate pain medicine and gastrostomy (feeding tube) use.

-Patients using MuGard noted a reduction of the severity of both clinically assessed and patient perceived symptoms of oral mucositis, resulting in RTOG scoring (the Radiation Therapy Oncology Group assessment score) falling to half of expected value.

-Marked reduction in pain experience during and following treatment, required milder pain medication for shorter periods of time, which has a positive impact on cost and other patient side effects such as drowsiness and constipation.

-MuGard use allowed patients to maintain oral nutrition and hydration for longer than usually seen, with a significant reduction in the use of supplements and gastrostomy feeding tubes.

-It was noted that patients using MuGard returned more quickly to a full and normal oral diet.

-MuGard was generally well tolerated, and clinicians were supportive of MuGard use based on the clearly evident benefits to the patient seen in the study.

“The findings in this study are both very encouraging, and consistent with the feedback from clinicians and patients in the field pertaining to the effectiveness of MuGard in treating the very debilitating side effect of oral mucositis,” said Jeffrey B. Davis, CEO of Access Pharmaceuticals, Inc.  He continued, “In addition to the specific clinical benefits mentioned in the study, we are encouraged at the related pharmoeconomic discussion of how MuGard can help to decrease healthcare costs through the reduction in the use of pain meds, reduction in the use of feeding tubes, and by providing for certain quality of life improvements that have both a significant clinical as well as pharmoeconomic benefit.”

About European Multidisciplinary Cancer Congress:

The 2011 European Multidisciplinary Cancer Congress is the combination of the 16th congress of the European CanCer Organisation (ECCO), the 36th congress of the European Society for Medical Oncology (ESMO) and the 30th congress of European Society for Therapeutic Radiology and Oncology (ESTRO).

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Dallas and New York, NY, September 07, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB:ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it has contracted with CuraScript, a healthcare subsidiary of  Express Scripts (NasdaqGS:ESRX), to expand its specialty pharmacy and third party logistics networks for its oral mucositis product, MuGard.  CuraScript Specialty Pharmacy (SPP), the specialty division of Express Scripts, will provide MuGard to the patients within their expansive  network.  In addition, Access has contracted with CuraScript Specialty Distribution, its third party logistics division, to warehouse MuGard and serve as its specialty distributor and wholesaler for specialty pharmacy providers.

“We are very excited about working with Access Pharmaceuticals as a fully integrated supply chain partner,” said Kevin Cast, Express Scripts’ Vice President of Strategy and Contracting, Pharma and Biotech.   He continued, “The award of an exclusive 3PL position and preferred Specialty Pharmacy position for MuGard is absolute validation of Express Scripts’ commitment to providing vital access solutions for pharmaceutical and biotech organizations.”

CuraScript Specialty Pharmacy is a wholly owned subsidiary of Express Scripts, one of the nation’s largest pharmacy benefit managers (PBMs).  CuraScript manages the largest number of exclusive Pharma/Biotech programs in the industry and has been involved in nearly every specialty product launch over the last eight years.  CuraScript currently services more than 1,800 payers that cover approximately 60 to 65 million lives.  CuraScript’s Third Party Logistics (3PL) services provide customized logistics programs, inventory management, consignment-based inventory, accounts receivable, and customer service functionality on behalf of Pharma/Biotech clients.

“We are pleased to be teaming up with CuraScript and Express Scripts to expand our specialty pharmacy and distribution capabilities,” said Anthony Mottola, Vice President Managed Care and Market Access, Access Pharmaceuticals, Inc.  He continued, “We are strongly committed to increasing MuGard market access for cancer patients undergoing radiation and chemotherapy and having a strong partner like CuraScript in place is a critical step in expanding our infrastructure to continue meeting the growing demand for MuGard.”

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

Investor Conference Call Reminder:

An investor conference call is scheduled to be held today at 11:00 am EDT.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. A replay of the call will be available starting on September 7th at 1:00 pm EDT, through September 21, 2011 until 11:59 pm EDT.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Investor Call Scheduled for Tomorrow, Wednesday, September 7^th at 11:00 a.m. EDT

Dallas, TX and New York, NY, September 06, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the Company’s management team will present at the Rodman & Renshaw Annual Healthcare Conference on Monday, September 12^th at 2:25p.m., in the Metropolitan West Room at the Waldorf Astoria Hotel, New York City.  Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation focused on the Company’s lead product for oral mucositis, MuGard and detail the development strategy for ongoing programs within its drug pipeline.

A live webcast of the presentation may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq20/accp .To arrange a meeting with Access management at the conference, please email Christine Berni, christine.berni@accesspharma.com.

Conference Call Reminder:

The investor conference call is scheduled to be held tomorrow, Wednesday, September 7, 2011 at 11:00 am EDT.  Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time. A replay of the call will be available starting on September 7^th at 1:00 pm EDT, through September 21, 2011 until 11:59 pm EDT.  Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Email

Print

Tweet

Digg!

Del.icio.us

Company Schedules Investor Conference Call For Wednesday, September 7th at 11:00AM EDT

Dallas, TX and New York, NY, August 16, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, has announced its second quarter 2011 investor conference call and the recent progress in its MuGard program. MuGard is a mucoadhesive oral wound rinse and coating that has been shown to be very effective in the management of oral mucositis, a debilitating side effect of many anticancer treatments. The investor conference call is scheduled to be held on Wednesday, September 7, 2011 at 11:00 am EDT. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.

Second Quarter 2011 Highlights:

Read more »

Email

Print

Tweet

Digg!

Del.icio.us

Public Relations Firm Focused on Increasing Media Awareness of Company’s

Oral Mucositis Treatment

Dallas, TX and New York, NY, August 05, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has hired Edelman, the leading full service global public relations firm, to support its media outreach initiatives.  Edelman will assist Access in implementing a media communications outreach program primarily aimed at introducing MuGard and building awareness of its ability to treat oral mucositis, a potentially debilitating disease which can cause painful inflammation and lesions of the mucous membranes lining the mouth and GI tract.

“Edelman has a great track record in conveying the value of company pipelines to a broad range of media outlets,” said Jeffrey Davis, Chief Executive Officer, Access Pharmaceuticals, Inc.  He continued, “We believe we are at the right time in the Access story and the commercialization of MuGard to expand our reach in within trade and consumer publications.   As we continue to execute on our strategy of growing the MuGard brand, capitalizing on Edelman’s strategic skills, creativity and global reach to communicate the benefit and control it provides cancer patients will be key in achieving our MuGard education and communications objectives.”

Bruce Hayes, general manager of Health for Edelman in the company’s New York office stated, “We are pleased that Access has made the decision to join our portfolio of health clients.  An emerging player in the cancer supportive care industry, Access is helping patients who suffer from oral mucositis. We are confident that our public engagement strategies will assist in building the MuGard brand and raising Access’ visibility among its key audiences.”

About Edelman

Edelman is the world’s largest independent public relations firm, with wholly-owned offices in 53 cities and 3,700 employees worldwide. Edelman was named Advertising Age’s top-ranked PR firm of the decade and one of its “2010 A-List Agencies” and “2010 Best Places to Work;” PRWeek’s “2011 Large PR Agency of the Year” and “2009 Agency of the Year;” European Excellence Awards’ “2010 Agency of the Year;” Holmes Report’s “Agency of the Decade” and “2009 Asia Pacific Consultancy of the Year;” and among Glassdoor’s top five “2011 Best Places to Work.” Visit http://www.edelman.com for more information.

About Access Pharmaceuticals, Inc.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.